Unlocking Biological Barriers to Deliver Molecular Science for Better Health
Where biotech innovation meets real skin results.
About N1 Life
Peptide delivery science built to cross biological barriers.
N1 Life is a biotechnology company spun out of Stanford University. Founded in 2019 in Silicon Valley, the company develops peptide-based delivery platforms and peptide drug conjugates that improve solubility, enhance penetration, and increase targeted efficacy in skincare and therapeutic applications.
Our Absotride platform is designed to help actives move across the skin barrier and reach the depth where they can do meaningful work, opening new possibilities for skincare essentials and advanced dermatology compounds.
Our Mission
Turn molecular design into delivery systems that are easier to translate.
We focus on the practical work between discovery and deployment, helping promising science move into real products, partnership programs, and measurable health outcomes.
The goal is simple: make the path from laboratory insight to useful application more direct, more efficient, and more dependable.
Our Science in Action
From molecular design to real-world products.
- AI-Designed Peptides expanding discovery with in-house skin penetration datasets.
- Targeted Delivery improving how high-value actives reach the right biological depth.
- Hair and Scalp Care exploring novel approaches for growth and scalp health programs.
Applications
Built for skincare, dermatology, and adjacent translational programs.
The platform is designed to support cosmetic and therapeutic use cases where formulation depth, penetration, and practical delivery all matter.
Core Values
Science advances humanity. Technology transforms lives.
Three principles keep every partnership grounded and keep the platform work focused on outcomes that matter.
Innovation
N1 Life bridges industry and academia with a technology-centered team focused on unmet cosmetic and therapeutic needs.
Sustainability
We pursue a sustainable development and partnership model designed to save time, resources, and energy across product programs.
Accessibility
Our delivery technologies aim to lower development cost and help novel treatments become more accessible and affordable.